Lunit Acquires AI-Enabled Breast Cancer Detection Platform Volpara for $193M

What You Should Know:

– South Korean AI leader Lunit has announced its intention to acquire Volpara, a global pioneer in AI-powered cancer detection software, in a landmark deal worth AUD 292M (USD 193M).

– Beyond market presence, it’s Volpara’s deep knowledge and extensive data that truly sets it apart. With over 100 million high-quality mammogram images in its repository, Volpara offers a treasure trove of insights that will supercharge Lunit’s AI capabilities and pave the way for groundbreaking solutions in medical imaging.

Why the Acquisition Matters

• Lunit gains a strong foothold in the U.S. market: Volpara’s presence in over 2,000 medical sites across the U.S. significantly expands Lunit’s reach and impact.
• Synergy of AI expertise: Combining Lunit’s AI prowess with Volpara’s extensive database of mammogram images (over 100 million!) will fuel the development of groundbreaking diagnostic solutions.
• Leadership in cancer care: This union positions the combined entity as a leading force in AI-driven cancer diagnostics and therapeutics, benefiting both healthcare professionals and patients.

“Lunit’s acquisition of Volpara signifies a pivotal moment in our commitment to advancing global cancer diagnostics. Volpara’s AI-powered mammography solutions, operational in over 2,000 U.S. medical sites, would catapult Lunit into the forefront of the American market,” said Brandon Suh, CEO of Lunit. “What sets Volpara apart is not just its market presence but the depth of knowledge embedded in its development process. With a robust repository of over 100 million high-quality mammogram images, Volpara’s contribution would supercharge Lunit’s AI capabilities, paving the way for groundbreaking solutions in medical imaging. This alliance would position us to lead innovation in cancer diagnostics and therapeutics, benefitting healthcare professionals and patients alike.”

diagnostics
therapeutics
medical
healthcare
ai
software